NYSEAMERICAN:AST - Asterias Biotherapeutics Stock Price, News, & Analysis

$0.94
0.00 (0.00 %)
(As of 05/30/2019)
Today's Range
$0.9450
Now: $0.9450
$0.9450
50-Day Range N/A
52-Week Range
$0.51
Now: $0.9450
$2.05
VolumeN/A
Average Volume136,653 shs
Market Capitalization$52.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:AST
Previous SymbolNYSEMKT:AST
CUSIPN/A
CIKN/A
Phone+1-510-4563805

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$52.60 million
Next Earnings DateN/A
OptionableOptionable

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.

Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to analysts' expectations of $2.81 million. View Asterias Biotherapeutics' Earnings History.

What price target have analysts set for AST?

3 equities research analysts have issued 12 month price targets for Asterias Biotherapeutics' shares. Their forecasts range from $6.00 to $11.00. On average, they anticipate Asterias Biotherapeutics' share price to reach $8.50 in the next year. This suggests a possible upside of 799.5% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics.

What is the consensus analysts' recommendation for Asterias Biotherapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics.

What are Wall Street analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (2/20/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of- the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer." (9/5/2018)

Has Asterias Biotherapeutics been receiving favorable news coverage?

News articles about AST stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Asterias Biotherapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the company's share price in the near term. View News Stories for Asterias Biotherapeutics.

Who are some of Asterias Biotherapeutics' key competitors?

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include BioTime (BTX), Synergy Pharmaceuticals (SGYP), Zynerba Pharmaceuticals (ZYNE), Sangamo Therapeutics (SGMO), Amarin (AMRN), Progenics Pharmaceuticals (PGNX), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Geron (GERN) and Micron Technology (MU).

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:
  • Mr. Michael H. Mulroy, CEO, Pres & Director (Age 53)
  • Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)
  • Dr. Katharine E. Spink, Consultant (Age 45)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 56)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43)

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $0.9450.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $52.60 million. View Additional Information About Asterias Biotherapeutics.

What is Asterias Biotherapeutics' official website?

The official website for Asterias Biotherapeutics is http://asteriasbiotherapeutics.com/.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  125 (Thanks for Voting!)
Underperform Votes:  111 (Thanks for Voting!)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel